ClinicalTrials.gg
CompletedNCT04968223SPIRITUpdated Dec 9, 2024

Neural Correlates of Social Touch and Interoceptive Perception As Potential Biomarker for Impaired Social Functioning

An observational study in Schizophrenia, sponsored by University of Oldenburg. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by University of Oldenburg · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
106
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 179 studies in Schizophrenia with a site in Germany — 17 open to participants now, 21 under way, none of them phase 3. Schizophrenia · Germany.

Enrollment
16th of 22
106 · median 250
Started
2021
with 8 others
Observational
22 of 179
1 open now
Registered
154th of 179
by date

Among the 179 studies in Schizophrenia with a site in Germany, this one is the 16th largest by enrollment of the 22 observational ones that give a count, is one of 9 that started in 2021, is one of 22 observational ones, and was the 154th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

17 of the 179 studies in Schizophrenia with a site in Germany are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Schizophrenia with a site in Germany, or all of them as a file.
02

Study summary

Recent studies have shown that certain biomarkers of schizophrenia could help to better assess the individual course of the disease and thus, contribute to more personalized treatment options. The aim of the SPIRIT study is to identify potential biomarkers for the prediction of disease-associated outcomes by investigating the neurobiological mechanisms of underlying schizophrenia-related dysfunctions.

Read the detailed description

Alterations in psychosocial functioning are evident from the prodromal phase of schizophrenia and play a crucial role in its chronic course. While recent studies have demonstrated the predictive validity of structural changes in the brain anatomy of patients with schizophrenia, there is a lack of studies assessing the predictive value of disease-associated alterations in the functional brain activity for symptom severity and psychosocial functioning in schizophrenia.

In this longitudinal, observational study, 60 patients with schizophrenia and 40 healthy subjects without family history of psychotic illness will be recruited to investigate differences in behavioural, physiological, and neural correlates of social touch and interoceptive perception between participant groups. Participants' symptom severity and psychosocial functioning level will be examined by a wide range of behavioural, physiological, and neural methods. Potential biomarkers will be identified by estimating the predictive value of initially performed methods on follow-up re-examination of clinical and psychosocial outcomes. Neural readouts include structural and functional magnetic resonance imaging (fMRI) measurements. The fMRI tasks will probe the processing of social touch and interoceptive perception; additionally resting-state connectivity will be assessed. To further investigate pathological distortions of social touch and interoceptive perception, bodily touch allowance maps will be measured and participants will perform a heart-beat discrimination task. Psychometric questionnaires and semi-structured interviews will be used to capture symptom load and level of psychosocial functioning. Long-term effects will be assessed by online questionnaires and semi-structured interviews via phone call 3- and 6 months after initial assessments. The investigators hypothesize that differences in the neural response to social touch as well as in the neural patterns of interoceptive perception could serve as potential biomarkers for psychosocial deficits during the course of the illness. Furthermore, the inclusion of those biomarkers in predictive models could improve the prediction of disease progression and thus, contribute to personalized therapy.

03

Conditions studied

  • Schizophrenia

Keywords

  • Biomarker-based prediction
  • Precision Psychiatry
  • Schizophrenia
  • Social functioning
  • Social Touch
  • Interoception
  • fMRI
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

In- and outpatients of the Department of Psychiatry, University of Oldenburg. Patients meeting the criteria for schizophrenia or schizoaffective disorder according to DSM-V will be included in the study. The patients' diagnosis will be verified via the structured clinical interview for DSM-V. Healthy subjects without family history of psychotic illness (control group). Control group will be matched to the patient sample.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is able to provide consent.
  • Diagnosis of schizophrenia or schizoaffective disorder according to
  • Control group: No psychiatric or neurological illness.
  • Fluent in German.

Exclusion criteria

Exclusion Criteria:

  • The participant does not fulfill requirements for MRI measurements according to safety guidelines.
  • Acute suicidality.
  • Current substance dependence.
  • A history of head trauma or neurological illness.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
106 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patient Group

    Patients with Schizophrenia

  • Control Group

    Healthy subjects without family history of psychotic illness

06

What researchers measure

Primary outcomes

  1. Neural responses in a social touch task

    Participants will be measured with functional magnetic resonance imaging (fMRI) while they perceive different types of social and non-social touch

    Time frame: One-time baseline assessment

  2. Behavioral responses in a social touch fMRI task

    Measured as behavioral ratings during the social touch fMRI task. During the social touch fMRI task, participants rate the comfort of the tactile stimuli on a visual analogue scale.

    Time frame: One-time baseline assessment

  3. Neural responses in an interoception fMRI task

    Participants will be measured with functional magnetic resonance imaging (fMRI) while they perform an interoception task

    Time frame: One-time baseline assessment

  4. Behavioral responses in an interoception fMRI task

    Measured by performance on the interoception task. During the interoception fMRI task, participants rate how intensely they perceived their heartbeat or their stomach on a visual analogue scale.

    Time frame: One-time baseline assessment

  5. Changes in clinician-rated symptom severity between baseline and follow-ups

    Measured by half-structured interviews (e.g. Positive and Negative Syndrome Scale (PANSS); range: 30-210; higher scores indicating more severe symptoms) for disease-related symptoms

    Time frame: Baseline, 3 and 6 months follow- up after initial baseline assessment

  6. Changes in self-reported symptom severity between baseline and follow-ups

    Measured by self-evaluation questionnaires (e.g. Self-assessment of Negative Symptoms (SNS); range 1-20; higher scores indicating more severe symptoms) for disease-related symptoms

    Time frame: Baseline, 3 and 6 months follow- up after initial baseline assessment

  7. Changes in clinician-rated social-role functioning between baseline and follow-ups

    Measured by the clinician-rated the social-role functioning scale (range: 1-10; higher scores indicating higher functioning)

    Time frame: Baseline, 3 and 6 months follow- up after initial baseline assessment

  8. Changes in self-reported social-role functioning levels between baseline and follow-ups

    Measured by the self-evaluation questionnaires for social-role functioning (e.g. Social Network Index (SNI); range 1-12; higher scores indicating higher functioning)

    Time frame: Baseline, 3 and 6 months follow-up after initial baseline assessment

Secondary outcomes

  1. Bodily maps of social touch

    Measured as performance on a bodily maps computer task

    Time frame: One-time baseline assessment

  2. Attitude towards social touch

    Measured by the self-evaluation questionnaire for social touch tolerance (e.g. Social Touch Questionnaire; range 0-4; higher scores indicating higher touch tolerance)

    Time frame: One-time baseline assessment

  3. Interoceptive accuracy

    Measured as performance on a heartbeat discrimination task

    Time frame: One-time baseline assessment

  4. Interoceptive awareness

    Measured by a self-evaluation questionnaire for interoceptive awareness (e.g. Multidimensional Assessment of Interoceptive Awareness (MAIA); range 0-5; higher scores indicating higher interoceptive awareness)

    Time frame: One-time baseline assessment

  5. Blood parameter

    Measured by schizophrenia related, Nuclear Magnetic Resonance spectroscopy (NMR) based metabolomics

    Time frame: One-time baseline assessment

  6. Urine parameter

    Measured by schizophrenia related, Nuclear Magnetic Resonance spectroscopy (NMR) based metabolomics

    Time frame: One-time baseline assessment

  7. Neural activity at resting state

    fMRI will be performed to measure BOLD-signal while participants lay in the MRI-scanner with eyes open.

    Time frame: One-time baseline assessment

  8. Structural connectivity measure

    fMRI will be performed to measure BOLD-signal while participants lay in the MRI-scanner with eyes open.

    Time frame: One-time baseline assessment

07

Study locations

1 site
  • Department of Psychiatry, University of Oldenburg
    Bad Zwischenahn, 26160, Germany
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in May 2024, 32 months.

Of 114 non-industry observational studies under Schizophrenia, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 114. This study's 32 months is below that.

Counting every sponsor, half of 136 studies reached it within 47 months; a quarter within 27 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jul 20, 2021
StartActual
Aug 16, 2021
Primary completionActual
May 15, 2024
CompletionActual
Nov 30, 2024
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04968223
Lead sponsor
University of Oldenburg
Collaborators
Danilo Postin, M.Sc.
Responsible party
Dirk Scheele (Deputy Lab Head, University of Oldenburg) — Principal investigator
First posted
Jul 20, 2021
Start date
Aug 16, 2021
Primary completion
May 15, 2024
Completion
Nov 30, 2024
Last update
Dec 9, 2024

Study contacts

René Hurlemann, Prof.
principal investigator · Department of Psychiatry, University of Oldenburg
Dirk Scheele, Dr.
principal investigator · Department of Psychiatry, University of Oldenburg
Danilo Postin, M.Sc.
study director · Department of Psychiatry, University of Oldenburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion